Literature DB >> 31199238

Followup imaging studies in metastatic castration-resistant prostate cancer: An individualized approach.

Myuran Thana1, Lori A Wood1.   

Abstract

Entities:  

Year:  2019        PMID： 31199238      PMCID： PMC6570598          DOI： 10.5489/cuaj.6033

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  9 in total

1.  Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302.

Authors:  Lisa J Martin; Shabbir M H Alibhai; Maria Komisarenko; Narhari Timilshina; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

2.  The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Authors:  Fred Saad; Kim N Chi; Antonio Finelli; Sebastien J Hotte; Jonathan Izawa; Anil Kapoor; Wassim Kassouf; Andrew Loblaw; Scott North; Ricardo Rendon; Alan So; Nawaid Usmani; Eric Vigneault; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

3.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Parker; S Gillessen; A Heidenreich; A Horwich
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

4.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Authors:  Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin
Journal:  Eur Urol       Date:  2017-06-24       Impact factor: 20.096

Review 5.  Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.

Authors:  Katherine S Virgo; Ethan Basch; D Andrew Loblaw; Thomas K Oliver; R Bryan Rumble; Michael A Carducci; Luke Nordquist; Mary-Ellen Taplin; Eric Winquist; Eric A Singer
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

6.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Christopher P Evans; Choung-Soo Kim; Go Kimura; Kurt Miller; Fred Saad; Anders S Bjartell; Michael Borre; Peter Mulders; Teuvo L Tammela; Teresa Parli; Suha Sari; Steve van Os; Ad Theeuwes; Bertrand Tombal
Journal:  Eur Urol       Date:  2016-07-28       Impact factor: 20.096

7.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Authors:  Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet
Journal:  Eur Urol       Date:  2016-08-31       Impact factor: 20.096

8.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

9.  Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

Authors:  A H Bryce; J J Alumkal; A Armstrong; C S Higano; P Iversen; C N Sternberg; D Rathkopf; Y Loriot; J de Bono; B Tombal; S Abhyankar; P Lin; A Krivoshik; D Phung; T M Beer
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-24       Impact factor: 5.554
  9 in total
  1 in total

1.  Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.

Authors:  Kathleen Ruchalski; Hyun J Kim; Michael Douek; Steven Raman; Maitraya Patel; Victor Sai; Antonio Gutierrez; Benjamin Levine; Cheryce Fischer; Martin Allen-Auerbach; Pawan Gupta; Heidi Coy; Bianca Villegas; Matthew Brown; Jonathan Goldin
Journal:  Cancer Imaging       Date:  2022-07-14       Impact factor: 5.605
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.